Comparison of the diagnostic accuracy of thoracic ultrasonography and portable chest X-ray in the diagnosis of ventilator-associated pneumonia

Comparison of the diagnostic accuracy of thoracic ultrasonography and portable chest X-ray in the diagnosis of ventilator-associated pneumonia - TUS-VAP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00011119

Enrollment

100

Registered

2016-10-04

Start date

2016-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-associated pneumonia J15

Interventions

Group 1: VAP positive: As soon as inclusion criteria are met (signs & symptoms suggestive of sepsis PLUS worsening respiratory function), microbiological sampling (bronchial suctioning ur bronchial la

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Mechanical ventilation • Intensive care unit treatment expected to be required for at least 48 hours at the time of screening • Presence of signs and symptoms suggestive for VAP (signs of worsening respiratory function (an increase of FiO2 by 0.15 or an increase of PEEP by > 2 mbar or a new onset of purulent sputum or a new onset of abnormal breath sounds) accompanied by signs and symptoms of systemic inflammation (temperature > 38°C or 12.0 x 109/l or a C-reactive protein (CRP) level > 87 mg/l or increased by 41 mg/l from the previous value)

Exclusion criteria

Exclusion criteria: • Established diagnosis of pneumonia • Surgery or severe injury to the thorax as the reason to the ICU-stay • Age 40 kg m-2 • Confirmed pregnancy (ß-HCG >10U/l)

Design outcomes

Primary

Measure	Time frame
The primary outcome is the diagnostic accuracy of TUS (Thoracic ultrasound) and portable chest X-ray in the detection of inflammatory consolidation in patients who have a diagnosis of VAP (Ventilator-associated pneumonia) confirmed by microbiologic laboratory results.	—

Secondary

Measure	Time frame
Incidence of unexpected findings(e.g. pleural effusion, pneumothorax), resource utilization and interobserver variability of each imaging modality	—

Countries

Germany, Switzerland

Contacts

Public ContactThomas Berlet

Abteilung für IntensivmedizinBonifatius-Hospital

thomas.berlet@hospital-lingen.de+49 591 910 1752

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026